Two to three sessions of 20-40 minute moderate-intensity cardio per week is sufficient
Initially developed to combat obesity, AOD-9604 has gained recognition for its ability to promote fat loss, boost metabolic function, and support joint health, all without the adverse effects typically associated with full-length HGH therapy
The 2025 IV pilot measured cardiac, hepatic, renal, thyroid, and glucose biomarkers and reported no abnormalities (Lee et al., 2025), which gives a sense of what those investigators considered worth checking
PDFV was found to: Promote migration and invasion of ESCs Reduce the expression of E-cadherins Overall, PDFV along with its precursor protein, namely VCAM-1, could very possibly be involved in the disease progression of OvE, and this goal is achieved through the reduction of E-cadherin expression
Theoretical considerations include: Potential interactions requiring monitoring: Other fat-loss agents or thermogenics (additive effects), growth hormone or growth hormone secretagogues (mechanism overlap), medications affecting glucose metabolism (monitor blood sugar despite AOD-9604s neutral glycemic effects)
